Evaluation the effect of meal pattern on Non alcoholic fatty liver disease

Evaluation the effect of meal pattern on hepatic fibrosis, steatosis, and enzymes, lipid profile, and anthropometric measurements in patient with non alcoholic fatty liver disease

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201010048982N2

Enrollment

112

Registered

2021-08-22

Start date

2021-06-20

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group 1: It will be recommended to eliminate their breakfast and during the day, in addition to lunch and dinner, receive two snacks in the evening and at the end of the n

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: older than 18 years of both sexes Non-alcoholic fatty liver disease diagnosed by FibroScan. Non-alcoholic fatty liver disease

Exclusion criteria

Exclusion criteria: Having special diets Viral hepatitis and ascites Alcohol consumption Diabetes mellitus kidney Diseases

Design outcomes

Primary

Measure	Time frame
Fibrosis. Timepoint: At the beginning and end of the study (beginning and end of 3 months). Method of measurement: FibroScan.;Liver enzymes. Timepoint: At the beginning and end of the study (beginning and end of 3 months). Method of measurement: At the beginning and end of the study, 5 cc of venous blood sample will be taken after 12 hours of fasting.;Steatosis. Timepoint: At the beginning and end of the study (beginning and end of 3 months). Method of measurement: At the beginning and end of the study, 5 cc of venous blood sample will be taken after 12 hours of fasting.;Lipid profile. Timepoint: At the beginning and end of the study (beginning and end of 3 months). Method of measurement: At the beginning and end of the study, 5 cc of venous blood sample will be taken after 12 hours of fasting.;Anthropometric measurements. Timepoint: At the beginning and end of the study (beginning and end of 3 months). Method of measurement: At the beginning and end of the study, 5 cc of venous blood sample will be taken after 12 hours of fasting.	—

Measure

Time frame

Fibrosis. Timepoint: At the beginning and end of the study (beginning and end of 3 months). Method of measurement: FibroScan.;Liver enzymes. Timepoint: At the beginning and end of the study (beginning and end of 3 months). Method of measurement: At the beginning and end of the study, 5 cc of venous blood sample will be taken after 12 hours of fasting.;Steatosis. Timepoint: At the beginning and end of the study (beginning and end of 3 months). Method of measurement: At the beginning and end of the study, 5 cc of venous blood sample will be taken after 12 hours of fasting.;Lipid profile. Timepoint: At the beginning and end of the study (beginning and end of 3 months). Method of measurement: At the beginning and end of the study, 5 cc of venous blood sample will be taken after 12 hours of fasting.;Anthropometric measurements. Timepoint: At the beginning and end of the study (beginning and end of 3 months). Method of measurement: At the beginning and end of the study, 5 cc of venous blood sample will be taken after 12 hours of fasting.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Mohammad Alizadeh

Oroumia University of Medical Sciences

far.alami28@gmail.com+98 45 3333 7906

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 9, 2026